Galmed Regains Nasdaq Compliance, Closing Minimum Bid Price Deficiency
GLMD sits 31% above its 52-week low of $3.289.
Summary
Galmed Pharmaceuticals regained compliance with Nasdaq's minimum bid price rule after maintaining a $1.00 closing price for 10 consecutive trading days, closing the matter.
Key Events · Legal and Risk Events · GLMD
-
Nasdaq Compliance Regained
Nasdaq confirmed on September 3, 2026 that Galmed regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2).
-
10-Day Bid Price Streak
The company's ordinary shares closed at $1.00 or higher for 10 consecutive trading days from August 20 through September 2, 2026.
-
Listing Deficiency Resolved
The matter is now closed, and Galmed's ordinary shares will continue to be listed and traded on The Nasdaq Stock Market.
-
Prior Deficiency Timeline
Nasdaq initially notified Galmed on January 29, 2026 of the deficiency, and the company received an additional 180-day compliance period after failing to cure it by July 28, 2026.
Analysis · GLMD · Life Sciences
A Nasdaq listing deficiency that had been outstanding since January 2026 has now been resolved. The company maintained a closing bid price of at least $1.00 for 10 consecutive trading days from August 20 through September 2, 2026, and Nasdaq confirmed compliance on September 3. This removes a delisting overhang that had been a material risk for the company.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLMD was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $3.29 to $13.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.